Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Chart of the Week: ASX retail offers pockets of value in softening conditions
Why slowing consumer spending could create opportunities in overlooked retail stocks.
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,799.10 | 170.10 | -1.90% |
| CAC 40 | 7,964.51 | 71.36 | -0.89% |
| DAX 40 | 25,199.19 | 200.02 | -0.79% |
| Dow JONES (US) | 50,906.05 | 443.87 | -0.86% |
| FTSE 100 | 10,606.00 | 30.71 | -0.29% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,861.06 | 63.52 | 0.24% |
| Nikkei 225 | 68,560.96 | 1,807.24 | 2.71% |
| NZX 50 Index | 13,810.51 | 23.88 | -0.17% |
| S&P 500 | 7,651.54 | 19.30 | -0.25% |
| S&P/ASX 200 | 8,619.10 | 170.20 | -1.94% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |